Trial · NCT04427787
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
NCT04427787, Phase 2, Unknown, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET. Trials, record NCT04427787. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04427787
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
- NCT number
- NCT04427787
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 69 participants, estimated
- Lead sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Conditions
- Metastatic Well Differentiated Neuroendocrine Neoplasm, Neuroendocrine Tumors
- Interventions
- Cabozantinib, Lanreotide
- First posted
- 2020-06-11
- Last updated
- 2021-09-05
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | 42 months | according to RECIST, v1.1 defined as complete response or partial response after treatment administration |
| Primary | Primary Safety Endpoint | 42 months | Adverse Events (AE) grade 3-5 according to NCI-CTCAE v5.0 grade |
| Secondary | Progression-free survival (PFS) | 42 months | defined as the time from first day of treatment administration until progression disease according to RECIST v 1.1 or death for every cause, whichever occurred first. |
| Secondary | Safety Endpoint | 42 months | Adverse Event (AE) all grade according to NCI-CTCAE v5.0 grade |
| Secondary | Clinical effectiveness endpoint | 42 months | Overall Survival (OS) defined as the time from first treatment administration until death whichever cause |
| Secondary | Exploratory objectives analysis | 42 months | the investigation of immunohistochemical tissue expression level of Mesenchymal Epithelial Transition (MET), AXL, vascular endothelial growth factor (VEGFR2) proteins. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04427787
GET https://conductscience.org/api/trials/v1/NCT04427787/registered